Clearside Biomedical, Inc. announced that safety and tolerability data from its recent OASIS clinical trial of CLS-AX (axitinib injectable suspension) were presented at the American Society of Retina Specialists (ASRS) 41st Annual Scientific Meeting. CLS-AX is a proprietary suspension formulation of the tyrosine kinase inhibitor (TKI) axitinib that provides high potency pan-VEGF inhibition delivered via Clearside's proprietary SCS Microinjector®?. The presentation, entitled, "Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy" was delivered by Rahul N. Khurana, MD, FACRS, Northern California Retina Vitreous Associates.

Dr. Khurana presented data from Clearside's OASIS Phase 1/2a clinical trial and Extension Study highlighting the excellent safety profile with no serious adverse events (SAEs), no adverse events (AEs) from inflammation, no vasculitis or vascular occlusion, and no treatment acute adverse events (TEAEs) related to study treatment. The presentation described the promising results from the 6-Month Extension Study at higher doses in Cohort 3 and Cohort 4. These cohorts showed signs of durability and a 77% - 85% reduction in treatment burden. Clearside's suprachoroidal delivery platform is also featured at ASRS in presentations related to several partner programs: Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Results of the Phase II AAVIATE Study; Suprachoroidal Delivery the RGX-314 Gene Therapy for Diabetic Retinopathy: The Phase II ALTITUDE Study; Phase 2 Trial of Belzupacap Sarotalocan (Bel-Sar, AU-011), a Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration:CLS-AX (axitinIB injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection.

Suprachoroidal injection of this proprietary suspension of axitinIB has demonstrated meaningful potential in preclinical studies in multiple species and in a Phase 1/2a wet AMD clinical trial in which CLS-AX was well tolerated and demonstrated an excellent safety profile. The Company's lead program, CLS-AX (axit inib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE®?

(triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. R risks and uncertainties that may cause actual results to differ materially include uncertainties in the conduct of clinical trials, Clearside's reliance on the conduct of clinical trials, the Company's reliance on SCS Microinjector is a proprietary suspension of Suprachoroidal injection of CLS-AX in the U.S. Patients With Persistent Activity After anti-VEGF Therapy' Therapy after Anti-VEGF Therapy' Therapy' Therapy' Therapy' therapy was delivered by Rahul N.Khurana, MD, FACS, Northern California Retina VitREous Associates. Dr.Khurana presented data from CleARSide's OASIS Phase 2b clinical testing.

The company developed and gained approval for its First product, XIPERE (triamcinolone Acetonide injection) for suprachoroid use, which is availablein the U.S. through an commercial partner. R risks and risks and uncertainties that may cause real results to differ materially include uncertainties include uncertainties include uncertainties in the conduct of the conduct of clinical trials, uncertainties in the conduct of clinical trial, Clearside's reliance in the conduct of clinical trials.